File downloaded on 2026-11-15
Source URL: https://medicines.health.europa.eu/veterinary/en/600000048854

Selehold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg

Authorised

- Selamectin

Product identification

Medicine name:
Selehold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg

Active substance:
Selamectin

Target species:
Dog
Cat

Route of administration:
Spot-on use

Product details

Active substance and strength:
Selamectin
15.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AA05

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Package description:
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution.Cardboard box containing 15 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution.Cardboard box containing 6 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution.Cardboard box containing 3 pipettes.
Translucent polypropylene unit-dose pipette with polyethylene or polyoxymethylene or polypropylene closure with spikepackaged into a laminated triplex bag composed of polyester, aluminium and polyethylene. 1 ml pipette containing 0.25 ml of solution.Cardboard box containing 1 pipette.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
30/01/2019

Manufacturing sites for batch release:
TAD Pharma GmbH
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
National Organization For Medicines

Authorisation number:
133023/31-12-2008/31-01-2019/K-0232506

Date of authorisation status change:
21/01/2022

Reference member state:
Ireland

Procedure number:
IE/V/0394/001

Concerned member states:
Belgium Bulgaria Croatia Czechia Estonia France Germany Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Updated on: 14/03/2026
Download